抗体偶联药物的药代动力学特征及其在消化道系统癌症治疗中的研究进展
Pharmacokinetics of antibody-drug conjugates and their research progress in the treatment of gastrointestinal malignancies
-
摘要: 消化道系统癌症的发病率和致死率位于世界前列, 对于传统化疗放疗效果不佳的患者, 亟需新型的治疗手段。近年来, 在精准医疗的时代背景下, 抗体偶联药物(antibody-drug conjugates, ADCs) 因其同时具有抗体的精准靶向优势和细胞毒性药物的高效杀伤优势而成为了生物医药领域炙手可热的研发产品, 获得了长足发展。然而由于ADCs复杂的基本结构及作用机制为其药代动力学研究带来了诸多困难与挑战, 是目前ADCs发展的最大阻力。因此, 全面深入地了解ADCs的药代动力学特性并加以改善利用对提升其在消化系统癌症治疗中的疗效具有重要的理论与现实意义。本文将从ADCs的基本结构组成及作用机制、药代动力学特性及其在消化系统癌症治疗中的研究进展做一较为翔实的介绍, 为ADCs的进一步研发提供参考。Abstract: The morbidity and mortality of gastrointestinal malignancies are the highest in the world. For patients with poor response to conventional chemotherapy, new treatment methods are urgently needed. In recent years, under the background of precision medicine, antibody-drug conjugates (ADCs) with high tumor specificity and potent toxicity have become a hot research spot in the field of biomedicine. However, due to the complex structure and mechanism of ADCs, its pharmacokinetic research is facing great challenges which are the biggest resistance to the development of ADCs at present. In this case, it is of great significance to understand the pharmacokinetic properties of ADCs and make use of it to improve the efficacy of ADCs in the treatment of gastrointestinal malignancies. Based on the basic composition and mechanism of ADCs, this review summarizes the pharmacokinetic properties of ADCs, discusses its recent advances in the treatment of gastrointestinal malignancies, in order to provide more references for follow-up research on ADCs.
下载: